Extended Data from APOLLO Phase 1 Trial Demonstrate Sustained Reduction in Lipoprotein(a) with Zerlasiran Treatment
Zerlasiran, a short interfering RNA (siRNA) agent, produces a prolonged and significant reduction in lipoprotein(a) [Lp(a)] levels in adults with elevated Lp(a), including those with atherosclerotic cardiovascular disease (ASCVD).